ArticleOncogene2000
Genetic determinants of response to chemotherapy in transgenic mouse mammary and salivary tumors.
Article in Oncogene, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 45 citations in OpenAlex.
- Monitoring Immune Cell Function Through Optical Imaging: a Review Highlighting Transgenic Mouse Models.Molecular imaging and biology · 2022Review
- Review
- A nanodroplet cell processing platform facilitating drug synergy evaluations for anti-cancer treatments.Scientific reports · 2019Article
- Establishment of a novel human lymphoblastic cell strain with the long arm of chromosome 11 aberration without MLL rearrangement.Scientific reports · 2017Article
- Immunocompromised and immunocompetent mouse models for head and neck squamous cell carcinoma.OncoTargets and therapy · 2016Review
- Comparison of effects of p53 null and gain-of-function mutations on salivary tumors in MMTV-Hras transgenic mice.PloS one · 2015Article
- Therapeutic efficacy of p53 restoration in Mdm2-overexpressing tumors.Molecular cancer research : MCR · 2014Article
- The mutant p53 mouse as a pre-clinical model.Oncogene · 2013Review
- A critical review of lipid-based nanoparticles for taxane delivery.Cancer letters · 2013Review
- Paclitaxel-induced apoptosis is BAK-dependent, but BAX and BIM-independent in breast tumor.PloS one · 2013Article
- p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer.Cancer cell · 2012Article
- Apoptosis and survival.Indian journal of human genetics · 2011Article
- Animal models of breast cancer for the study of pathogenesis and therapeutic insights.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2009Review
- Murine models to evaluate novel and conventional therapeutic strategies for cancer.The American journal of pathology · 2007Review
- Effects of phosphorothioate anti-sense oligodeoxynucleotides on colorectal cancer cell growth and telomerase activity.World journal of gastroenterology · 2004Article
- A bioinformatics-based strategy identifies c-Myc and Cdc25A as candidates for the Apmt mammary tumor latency modifiers.Genome research · 2002Article
- Telomeres and telomerase in hematologic neoplasia.Oncogene · 2002Review
- Knockout and transgenic mice of Trp53: what have we learned about p53 in breast cancer?Breast cancer research : BCR · 2002Review
- Mouse models for breast cancer.Breast cancer research : BCR · 2000Review
Corrections and comments
- Commented on by
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Several transgenic mouse tumor models were utilized to explore how specific genetic alterations affect the tumor cell response to chemotherapeutic agents in vivo. Specifically, MMTV-ras transgenic mice were interbred to p53 knock-out mice to create a model for assessing the role of p53 in chemotherapeutic responses. In addition, MMTV-ras tumors were compared to MMTV-myc and MMTV-ras/myc tumors. Mice of each genotype reproducibly develop mammary and/or salivary tumors, but tumor growth dynamics vary considerably between genotypes. MMTV-ras/p53-/- tumors exhibit higher S phase fractions than MMTV-ras/p53+/+ tumors, although both tumor types display very low apoptosis levels. In contrast, MMTV-myc tumors exhibit both high S phase fractions and spontaneous apoptosis levels. Tumor-bearing mice of each genotype were treated with either doxorubicin or paclitaxel, and effects on overall tumor growth, cell cycle distribution and apoptosis were evaluated. Surprisingly, neither agent efficiently induced apoptosis in any of the tumor models, including those with wildtype p53. Rather, tumor responses were mediated primarily by changes in cell cycle distribution. However, the spontaneous apoptosis levels did serve as a predictor of tumor growth response, in that only those tumors with high pretreatment apoptosis levels underwent significant regression following treatment with either agent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.